PFE - Pfizer Inc.

NYSE - NYSE Delayed price. Currency in USD
36.42
+0.18 (+0.50%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close36.24
Open36.30
Bid0.00 x 0
Ask0.00 x 0
Day's range36.03 - 36.42
52-week range29.83 - 36.60
Volume17,502,245
Avg. volume17,078,335
Market cap216.6B
Beta1.09
PE ratio (TTM)26.64
EPS (TTM)1.37
Earnings date31 Oct 2017
Forward Dividend & Yield1.28 (3.53%)
Ex-dividend date2017-11-09
1y target est38.30
Trade prices are not sourced from all markets
  • Glaxo (GSK) Q3 Earnings: Will it Deliver a Beat Yet Again?
    Zacksyesterday

    Glaxo (GSK) Q3 Earnings: Will it Deliver a Beat Yet Again?

    The performance of GlaxoSmithKline plc's (GSK) new products is likely to be good. Vaccines acquired from Novartis are likely to drive revenues and ease the impact of the loss of key drug, Advair .

  • 3 High-Yield Pharmaceutical Stocks
    Motley Foolyesterday

    3 High-Yield Pharmaceutical Stocks

    High-yield pharma stocks are rare, but these three offer comparatively fat payouts.

  • Market Realistyesterday

    What’s Driving Economic Moats

    "How Moats Translate into Sustainable Competitive Advantages" is a five-part moat investing education series that explores the primary sources of economic moats.

  • Healthcare ETFs Head to Head: XLV vs. VHT
    Zacks2 days ago

    Healthcare ETFs Head to Head: XLV vs. VHT

    Head to head comparison of two Healthcare ETFs, XLV and VHT.

  • Conatus Entrusts Keith W. Marshall With Key Management Roles
    Zacks2 days ago

    Conatus Entrusts Keith W. Marshall With Key Management Roles

    Conatus Pharmaceuticals (CNAT) announced the appointment of Keith W. Marshall as executive vice president, chief operating officer and chief financial officer.

  • Barrons.com2 days ago

    4 Cheap Stock Picks for the Impatient

    General Motors stock has a rare combination of a breakdown valuation and zippy price momentum. That is, it trades at eight times forward earnings estimates, making it less than half as expensive as the ...

  • Market Realist2 days ago

    Inside Pfizer’s Performance in 3Q17

    PFE stock rose ~7.3% in 3Q17 and has risen ~11.3% YTD (year-to-date) as of October 16.

  • 2 Great Stocks For Retirees
    Motley Fool2 days ago

    2 Great Stocks For Retirees

    Find out what makes this pair of big pharma stocks a perfect fit for recent retirees looking to bolster their income.

  • 3 High-Yield Stocks for Conservative Investors
    Motley Fool2 days ago

    3 High-Yield Stocks for Conservative Investors

    These solid businesses with great dividend yields hit the sweet spot for conservative investors.

  • The Wall Street Journal3 days ago

    [$$] Reckitt Makeover Clears Way for Pfizer Bid

    The London-listed consumer group is doing what activist Nelson Peltz wants Procter & Gamble to do—but M&A may be an ulterior motive.

  • What to Expect from Big Pharmas After J&J's Solid Q3 Results?
    Zacks3 days ago

    What to Expect from Big Pharmas After J&J's Solid Q3 Results?

    Large-cap pharmas are expected to report encouraging third-quarter results, following J&J's earnings beat. Five out of the six companies are expected to deliver earnings beat this quarter.

  • Here's Why Ignyta Stock Soared as Much as 27.5% Today
    Motley Fool3 days ago

    Here's Why Ignyta Stock Soared as Much as 27.5% Today

    The biopharma's lead drug candidate has strong potential based on a sneak peek at midstage trial data.

  • Reckitt to reshape as sales growth evaporates
    Reuters3 days ago

    Reckitt to reshape as sales growth evaporates

    Britain's Reckitt Benckiser will split its business into two divisions -- consumer healthcare and home and hygiene products -- to try to revive sales that are set to stall this year. It hopes to improve performance in its newly expanded health business, while bringing greater focus and accountability to its slower-growth home and hygiene business. Reckitt, whose products range from Durex condoms to Lysol disinfectant, has blamed fallout from a cyber attack, a failed product launch and a safety scandal in South Korea for its lacklustre sales.

  • Pfizer's Advil May Be Just the Thing for Sickly Reckitt
    Bloomberg3 days ago

    Pfizer's Advil May Be Just the Thing for Sickly Reckitt

    The problem is getting shareholders to back a cash call to pay for it.

  • Reuters4 days ago

    Reckitt Benckiser to form two business units for better focus

    Reckitt Benckiser (RB.L) plans to reorganise its business into two distinct units, one for health and the other for hygiene and home products, as it tries to improve its flagging performance. The maker of Durex condoms, Nurofen tablets and Dettol cleaners announced the restructuring on Wednesday, along with its third-quarter sales figures. The British company made the decision to restructure after its June acquisition of U.S. baby formula maker Mead Johnson, which will account for roughly half of the larger health unit's sales.

  • Reckitt CEO Focuses on Health, Looking Beyond Worst Year
    Bloomberg4 days ago

    Reckitt CEO Focuses on Health, Looking Beyond Worst Year

    Reckitt Benckiser Group Plc separated its home-care and health businesses, sharpening its focus on brands such as Durex condoms and Enfamil baby formula after a second cut in the sales forecast this year....

  • Reuters - UK Focus4 days ago

    Reckitt Benckiser to form two business units for better focus

    LONDON, Oct (Shenzhen: 000069.SZ - news) 18 (Reuters) - Reckitt Benckiser (Xetra: A0M1W6 - news) plans to reorganise its business into two distinct units, one for health and the other for hygiene and home products, as it tries to improve its flagging performance. The British company made the decision to restructure after its June acquisition of U.S. baby formula maker Mead Johnson, which will account for roughly half of the larger health unit's sales. "Here is the perfect opportunity for us to be able to create a proper leader in consumer health with the expertise and the focus that is needed to drive true leadership ... while at the same time unleash the potential of our hygiene/home portfolio by providing focus and accountability," Chief Executive Rakesh Kapoor told Reuters.

  • Forbes4 days ago

    Tiny Ignyta's Lung Cancer Drug Bested Pfizer's. Probably. Will We Ever Know For Sure?

    Results of a 32-patient study of a drug made by Ignyta Pharmaceuticals, a San Diego-based drugmaker, are a best case scenario for the company. The drug shrank tumors in 79% of patients and kept workingabout 10 months longer than the current drug, Pfizer’s Xalkori, did in earlier clinical trials.

  • Aerie (AERI) Up on FDA Review Committee Result for Rhopressa
    Zacks4 days ago

    Aerie (AERI) Up on FDA Review Committee Result for Rhopressa

    Shares of Aerie Pharmaceuticals, Inc. (AERI) have moved up 15.8% in the last week on positive news for its lead drug, Rhopressa.

  • J&J (JNJ) Beats on Q3 Earnings, Actelion Buyout Drives Sales
    Zacks4 days ago

    J&J (JNJ) Beats on Q3 Earnings, Actelion Buyout Drives Sales

    J&J (JNJ) reported better-than-expected third-quarter 2017 results and raised its 2017 sales and profit outlook.

  • Zacks Industry Outlook Highlights: Gilead, Teva, Pfizer and Amgen
    Zacks4 days ago

    Zacks Industry Outlook Highlights: Gilead, Teva, Pfizer and Amgen

    Zacks Industry Outlook Highlights: Gilead, Teva, Pfizer and Amgen

  • Forbes4 days ago

    The Blockbuster That Wasn't -- A CETP Inhibitor Post-Mortem

    The quest for the “holy grail” of cardiovascular therapy - a drug that dramatically lowered LDL-c and raised HDL-c and which would hopefully reverse atherosclerosis - has ended ignominiously.

  • Pharma Industry Outlook - October 2017
    Zacks5 days ago

    Pharma Industry Outlook - October 2017

    Pharma Industry Outlook - October 2017

  • Biotech, pharma shares drop after Trump says ‘drug prices are out of control’
    CNBC5 days ago

    Biotech, pharma shares drop after Trump says ‘drug prices are out of control’

    "Prescription drug prices are out of control. The drug prices have gone through the roof," Trump says at a Cabinet meeting.

  • Forbes5 days ago

    The Cost Of Developing Drugs Is Insane. That Paper That Says Otherwise Is Insanely Bad

    The pharmaceutical industry puts the cost of bringing a medicine from invention to pharmacy shelves at $2.7 billion. A new paper says it is 'just' $648 million. Unfortunately for pharmaceutical investors and people fighting to control drug prices, alike, the new number doesn’t stand up scrutiny.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes